Compare ULH & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULH | CCCC |
|---|---|---|
| Founded | 1932 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 354.9M | 404.7M |
| IPO Year | 2004 | 2020 |
| Metric | ULH | CCCC |
|---|---|---|
| Price | $15.79 | $3.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $20.00 | $12.20 |
| AVG Volume (30 Days) | 52.0K | ★ 2.2M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,461,708,000.00 | $35,947,000.00 |
| Revenue This Year | $2.73 | N/A |
| Revenue Next Year | $5.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $11.73 | $1.36 |
| 52 Week High | $30.76 | $4.60 |
| Indicator | ULH | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 43.70 | 56.34 |
| Support Level | $14.82 | $2.10 |
| Resistance Level | $18.76 | $4.60 |
| Average True Range (ATR) | 1.05 | 0.41 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 12.74 | 41.02 |
Universal Logistics Holdings Inc is an asset-light provider of customized transportation and logistics solutions throughout the United States, and in Mexico, Canada, and Colombia. It offers services such as truckload, brokerage, intermodal, dedicated, and value-added services. The firm has three reportable segments, namely contract logistics, intermodal, and trucking. The company generates the key revenue from Contract Logistics, which provides value-added and dedicated transportation services to support inbound and internal logistics requirements of industrial manufacturers and retailers, generally under contractual arrangements of one year or longer. Geographically, the firm generates the majority of its revenue from the United States, followed by Mexico, Canada, and Colombia.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.